Global optimization using Derringer's desirability function: enantioselective determination of ketoprofen in formulations and in biological matrices

• Autorzy: Sivakumar T. , Manavalan R. , Valliappan K.
• Języki publikacji: EN

Abstrakty

EN

A reversed-phase high-performance liquid chromatographic method for separation of the enantiomers of ketoprofen in formulations and in plas-ma matrices has been developed and optimized. A central composite design was used to develop response models and Derringer’s desirability function was then used for simultaneous optimization of chiral resolution and analysis time. This procedure enabled discovery of two separate sets of opti-mum conditions for analysis of quality-control samples and plasma samples within the experimental domain. The optimum conditions predicted for quality-control samples were acetonitrile–dipotassium hydrogen phosphate buffer (10 mΜ, pH 6.5)–triethylamine 56:44:0.05 (/ν) as νmobile phase and 1.13 mL min-1 as flow rate. Use of these conditions enabled baseline separation of the enantiomers of ketoprofen in approximately 4.2 min, which is quicker than the previously optimized method. The method was suitable for routine analysis of the enantiomers of ketoprofen in a commercial pharmaceutical preparation and in plasma samples.

• Wydawca: University of Silesia in Katowice ; Akademiai Kiado
• Czasopismo: Acta Chromatographica
• Rocznik: 2007
• Tom: No. 19
• Strony: 29--47
• Opis fizyczny: Bibliogr. 37 poz., rys., tab.

Twórcy

autor

Sivakumar T.

autor

Manavalan R.

autor

Valliappan K.

• Department of Pharmacy, Faculty of Engineering and Technology, Annamalai University, Annamalainagar, Tamil Nadu-608 002, India

Bibliografia

• [1] Z. Guoa, H. Wang, and Y. Zhang, J. Pharm. Biomed. Anal., 41, 310 (2006)
• [2] A.J. Hutt and J. Caldwell, Clin. Pharmacokinet., 9, 371 (1984)
• [3] K. Valliappan, K. Kannan, T. Sivakumar, and R. Manavalan, J. Appl. Biomed., 4, 153 (2006)
• [4] E. Castro, A. Soraci, F. Fogel, and O. Tapia, J. Vet. Pharmacol. Ther., 23, 265 (2000)
• [5] R.T. Foster and F. Jamali, Drug Metab. Dispos., 16, 623 (1988)
• [6] A.K. Arifah, M.F. Landoni, S.P. Frean, and P. Lees, Am. J. Vet. Res., 62, 77 (2001)
• [7] R.T. Foster and F. Jamali, J. Chromatogr., 416, 388 (1987)
• [8] M.A. Solínis, Y. de la Cruz, R.M. Hernández, A.R. Gascón, B. Calvo, and J.L. Pedraz, Int. J. Pharm., 239, 61 (2002)
• [9] K. Valliappan, K. Kannan, R. Manavalan, and C. Muralidharan, Indian J. Pharm. Sci., 65, 253 (2003)
• [10] S.P. Duddu, M. Vakilynejad, F. Jamali, and D.J.W. Grant, Pharm. Res., 10, 1648 (1993)
• [11] M.H. Ossipov, T.P. Jerussi, K. Ren, H. Sun, and F. Porreca, Pain, 87, 193 (2000)
• [12] N.G. Grubb, D.W. Rudy, and S.D. Hall, J. Chromatogr. B, 678, 237 (1996)
• [13] K. Valliappan, Indian J. Pharm. Sci., 65, 273 (2005)
• [14] E. Smet, L. Staelens, Y. Vander Heyden, and W.R.G. Baeyens, Chirality, 13, 556 (2001)
• [15] E. Ameyibor and J.T. Stewart, J. Pharm. Biomed. Anal., 17, 83 (1998)
• [16] K. Valliappan, K. Kannan, R. Manavalan, and C. Muralidharan, Indian J. Chem., 41A, 1334 (2002)
• [17] S.N. Deming, J. Chromatogr., 550, 15 (1991)
• [18] International Conference on Harmonization (ICH), Q2A: Text on Validation of Analytical Procedures: Definitions and Terminology, Vol. 60, US FDA Federal Register, 1995
• [19] International Conference on Harmonization (ICH), Q2B: Validation of Analytical Procedures: Methodology, Vol. 62, US FDA Federal Register, 1997
• [20] R.H. Myers and D. Montgomery, Response Surface Methodology: Process and Product Optimization using Designed Experiments, Wiley, New York, 1995
• [21] J. Gabrielsson, N.-O. Lindberg, and T. Lundstedt, J. Chemometr., 16, 141 (2002)
• [22] S.L.C. Ferreira, R.E. Bruns, E.G.P. da Silva, W.N.L. dos Santos, C.M. Quintella, J.M. David, J.B. de Andrade, M.C. Breitkreitz, I.C.S.F. Jardim, and B.B. Neto, J. Chromatogr. A, 1158, 2 (2007)
• [23] T. Sivakumar, R. Manavalan, C. Muralidharan, and K. Valliappan, J. Pharm. Biomed. Anal., 43, 1842 (2007)
• [24] T. Sivakumar, R. Manavalan, C. Muralidharan, and K. Valliappan, J. Sep. Sci., in press
• [25] S. Björkman, J. Chromatogr., 339, 339 (1985)
• [26] J.C. Parajo, J.L. Alonso, M.A. Lage, and D. Vazquez, Bioprocess Eng., 8, 129 (1992)
• [27] T. Lundstedt, E. Seifert, L. Abramo, B. Thelin, Å. Nyström, J. Pettersen, and R. Bergman, Chemometr. Intell. Lab. Syst., 42, 3 (1998)
• [28] Q.H. Beg, V. Sahai, and R. Gupta, Process Biochem., 39, 203 (2003)
• [29] T.N. Decaestecker, W.E. Lambert, C.H. Van Peteghem, D. Deforce, and J.F. Van Bocxlaer, J. Chromatogr. A, 1056, 57 (2004)
• [30] G. Derringer and R. Suich, J. Qual. Technol., 12, 214 (1980)
• [31] P. Wester, J. Gottfries, K. Johansson, F. Klintebäck, and B. Winblad, J. Chromatogr., 415, 261 (1987)
• [32] K. Danzer and L.A. Currie, Pure Appl. Chem., 70, 993 (1998)
• [33] W.G. Cochran, Ann. Eugenics., 11, 47 (1941)
• [34] T. Sivakumar, R. Manavalan, and K. Valliappan, Acta Chromatogr., 18, 130 (2007)
• [35] S. Ahuja and S. Scypinski (Eds) Handbook of Modern Pharmaceutical Analysis, Academic Press, New York, 2001, pp. 415–443
• [36] R. Sistla, V.S.S.K. Tata, Y.V. Kashyap, D. Chandrasekar, and P.V. Diwan, J. Pharm. Biomed. Anal., 39, 517 (2005)
• [37] J. Ermer and J.H.M. Miller (Eds) Method Validation in Pharmaceutical Analysis: A Guide to Best Practice, Wiley–VCH, Weinheim, 2005, pp. 195–226